{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-23-000394","form_type":"8-K","ticker":"CFOR","cik":"0001293818","company_name":"CapForce Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.259920+00:00","generated_at":"2026-06-17T08:58:27.153731+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OpGen reports FY2022 revenue $2.6M, down 40% YoY; guides FY2023 revenue $4-5M","bullets":["FY2022 total revenue ~$2.6M vs $4.3M in 2021; Q4 revenue $722K, down 48% YoY but up 61% QoQ.","Operating expenses $37.2M for FY2022, including $12.3M goodwill and IPR&D impairment charges.","Cash and equivalents $7.4M at Dec 31, 2022, down from $36.1M; recent $7.5M public offering closed.","FY2023 guidance: revenue $4-5M; net cash consumption $4.5-5M per quarter; EIB loan restructuring discussions for EUR 3M due June 2023.","Unyvero UTI FDA De Novo submission expected early Q2 2023; ARESiss first US commercial orders received."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-23-000394","json":"https://secwatch.observer/filing/0001079973-23-000394.json","markdown":"https://secwatch.observer/filing/0001079973-23-000394.md","text":"https://secwatch.observer/filing/0001079973-23-000394.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1293818/000107997323000394/0001079973-23-000394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1293818/000107997323000394/opgen_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:58:27.153731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa3f42b4542e647e2713eac6efa2796aa4f40a8d","claim":"CapForce Inc. reported full year ended December 31, 2022 results: revenue approximately $2.6 million. Guidance reaffirmed.","evidence_excerpt":"Its total revenue for 2022 was approximately $2.6 million which was in line with the Company's most recent guidance.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293818/000107997323000394/0001079973-23-000394-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2022"},{"label":"Revenue","value":"approximately $2.6 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"cb08208e1f5d9a28c4166535a0cfafd7de4e4852","claim":"CapForce Inc. reported the fourth quarter of 2022 results: revenue approximately $722 thousand.","evidence_excerpt":"OpGen's revenue for the fourth quarter of 2022 was approximately $722 thousand.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293818/000107997323000394/0001079973-23-000394-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Revenue","value":"approximately $722 thousand"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}